Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer

Jianneng Li, Mohammad Alyamani, Ao Zhang, Kai Hsiung Chang, Michael Berk, Zhenfei Li, Ziqi Zhu, Marianne Petro, Cristina Magi-Galluzzi, Mary Ellen Taplin, Jorge A. Garcia, Kevin Courtney, Eric A. Klein, Nima Sharifi

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Prostate cancer is driven by androgen stimulation of the androgen receptor (AR). The next-generation AR antagonist, enzalutamide, prolongs survival, but resistance and lethal disease eventually prevail. Emerging data suggest that the glucocorticoid receptor (GR) is upregulated in this context, stimulating expression of AR-target genes that permit continued growth despite AR blockade. However, countering this mechanism by administration of GR antagonists is problematic because GR is essential for life. We show that enzalutamide treatment in human models of prostate cancer and patient tissues is accompanied by a ubiquitin E3-ligase, AMFR, mediating loss of 11β-hydroxysteroid dehydrogenase-2 (11β-HSD2), which otherwise inactivates cortisol, sustaining tumor cortisol concentrations to stimulate GR and enzalutamide resistance. Remarkably, reinstatement of 11β-HSD2 expression, or AMFR loss, reverses enzalutamide resistance in mouse xenograft tumors. Together, these findings reveal a surprising metabolic mechanism of enzalutamide resistance that may be targeted with a strategy that circumvents a requirement for systemic GR ablation.

Original languageEnglish (US)
Article numbere20183
JournaleLife
Volume6
DOIs
StatePublished - Feb 13 2017

Fingerprint

Glucocorticoid Receptors
Metabolism
Tumors
Prostatic Neoplasms
Adrenal Cortex Hormones
Cells
Androgen Receptors
11-beta-Hydroxysteroid Dehydrogenases
Neoplasms
Hydrocortisone
Androgen Receptor Antagonists
Disease Resistance
Ubiquitin-Protein Ligases
Ablation
Heterografts
Androgens
Genes
MDV 3100
Tissue
Survival

ASJC Scopus subject areas

  • Neuroscience(all)
  • Medicine(all)
  • Immunology and Microbiology(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Li, J., Alyamani, M., Zhang, A., Chang, K. H., Berk, M., Li, Z., ... Sharifi, N. (2017). Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. eLife, 6, [e20183]. https://doi.org/10.7554/eLife.20183

Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. / Li, Jianneng; Alyamani, Mohammad; Zhang, Ao; Chang, Kai Hsiung; Berk, Michael; Li, Zhenfei; Zhu, Ziqi; Petro, Marianne; Magi-Galluzzi, Cristina; Taplin, Mary Ellen; Garcia, Jorge A.; Courtney, Kevin; Klein, Eric A.; Sharifi, Nima.

In: eLife, Vol. 6, e20183, 13.02.2017.

Research output: Contribution to journalArticle

Li, J, Alyamani, M, Zhang, A, Chang, KH, Berk, M, Li, Z, Zhu, Z, Petro, M, Magi-Galluzzi, C, Taplin, ME, Garcia, JA, Courtney, K, Klein, EA & Sharifi, N 2017, 'Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer', eLife, vol. 6, e20183. https://doi.org/10.7554/eLife.20183
Li, Jianneng ; Alyamani, Mohammad ; Zhang, Ao ; Chang, Kai Hsiung ; Berk, Michael ; Li, Zhenfei ; Zhu, Ziqi ; Petro, Marianne ; Magi-Galluzzi, Cristina ; Taplin, Mary Ellen ; Garcia, Jorge A. ; Courtney, Kevin ; Klein, Eric A. ; Sharifi, Nima. / Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. In: eLife. 2017 ; Vol. 6.
@article{4112413c4ada4a1d9601bb94305b1284,
title = "Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer",
abstract = "Prostate cancer is driven by androgen stimulation of the androgen receptor (AR). The next-generation AR antagonist, enzalutamide, prolongs survival, but resistance and lethal disease eventually prevail. Emerging data suggest that the glucocorticoid receptor (GR) is upregulated in this context, stimulating expression of AR-target genes that permit continued growth despite AR blockade. However, countering this mechanism by administration of GR antagonists is problematic because GR is essential for life. We show that enzalutamide treatment in human models of prostate cancer and patient tissues is accompanied by a ubiquitin E3-ligase, AMFR, mediating loss of 11β-hydroxysteroid dehydrogenase-2 (11β-HSD2), which otherwise inactivates cortisol, sustaining tumor cortisol concentrations to stimulate GR and enzalutamide resistance. Remarkably, reinstatement of 11β-HSD2 expression, or AMFR loss, reverses enzalutamide resistance in mouse xenograft tumors. Together, these findings reveal a surprising metabolic mechanism of enzalutamide resistance that may be targeted with a strategy that circumvents a requirement for systemic GR ablation.",
author = "Jianneng Li and Mohammad Alyamani and Ao Zhang and Chang, {Kai Hsiung} and Michael Berk and Zhenfei Li and Ziqi Zhu and Marianne Petro and Cristina Magi-Galluzzi and Taplin, {Mary Ellen} and Garcia, {Jorge A.} and Kevin Courtney and Klein, {Eric A.} and Nima Sharifi",
year = "2017",
month = "2",
day = "13",
doi = "10.7554/eLife.20183",
language = "English (US)",
volume = "6",
journal = "eLife",
issn = "2050-084X",
publisher = "eLife Sciences Publications",

}

TY - JOUR

T1 - Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer

AU - Li, Jianneng

AU - Alyamani, Mohammad

AU - Zhang, Ao

AU - Chang, Kai Hsiung

AU - Berk, Michael

AU - Li, Zhenfei

AU - Zhu, Ziqi

AU - Petro, Marianne

AU - Magi-Galluzzi, Cristina

AU - Taplin, Mary Ellen

AU - Garcia, Jorge A.

AU - Courtney, Kevin

AU - Klein, Eric A.

AU - Sharifi, Nima

PY - 2017/2/13

Y1 - 2017/2/13

N2 - Prostate cancer is driven by androgen stimulation of the androgen receptor (AR). The next-generation AR antagonist, enzalutamide, prolongs survival, but resistance and lethal disease eventually prevail. Emerging data suggest that the glucocorticoid receptor (GR) is upregulated in this context, stimulating expression of AR-target genes that permit continued growth despite AR blockade. However, countering this mechanism by administration of GR antagonists is problematic because GR is essential for life. We show that enzalutamide treatment in human models of prostate cancer and patient tissues is accompanied by a ubiquitin E3-ligase, AMFR, mediating loss of 11β-hydroxysteroid dehydrogenase-2 (11β-HSD2), which otherwise inactivates cortisol, sustaining tumor cortisol concentrations to stimulate GR and enzalutamide resistance. Remarkably, reinstatement of 11β-HSD2 expression, or AMFR loss, reverses enzalutamide resistance in mouse xenograft tumors. Together, these findings reveal a surprising metabolic mechanism of enzalutamide resistance that may be targeted with a strategy that circumvents a requirement for systemic GR ablation.

AB - Prostate cancer is driven by androgen stimulation of the androgen receptor (AR). The next-generation AR antagonist, enzalutamide, prolongs survival, but resistance and lethal disease eventually prevail. Emerging data suggest that the glucocorticoid receptor (GR) is upregulated in this context, stimulating expression of AR-target genes that permit continued growth despite AR blockade. However, countering this mechanism by administration of GR antagonists is problematic because GR is essential for life. We show that enzalutamide treatment in human models of prostate cancer and patient tissues is accompanied by a ubiquitin E3-ligase, AMFR, mediating loss of 11β-hydroxysteroid dehydrogenase-2 (11β-HSD2), which otherwise inactivates cortisol, sustaining tumor cortisol concentrations to stimulate GR and enzalutamide resistance. Remarkably, reinstatement of 11β-HSD2 expression, or AMFR loss, reverses enzalutamide resistance in mouse xenograft tumors. Together, these findings reveal a surprising metabolic mechanism of enzalutamide resistance that may be targeted with a strategy that circumvents a requirement for systemic GR ablation.

UR - http://www.scopus.com/inward/record.url?scp=85013498415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013498415&partnerID=8YFLogxK

U2 - 10.7554/eLife.20183

DO - 10.7554/eLife.20183

M3 - Article

C2 - 28191869

AN - SCOPUS:85013498415

VL - 6

JO - eLife

JF - eLife

SN - 2050-084X

M1 - e20183

ER -